ClinVar Miner

Submissions for variant NM_001065.4(TNFRSF1A):c.269C>T (p.Thr90Ile)

gnomAD frequency: 0.00001  dbSNP: rs34751757
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001078480 SCV000760386 likely benign TNF receptor-associated periodic fever syndrome (TRAPS) 2023-11-27 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000756797 SCV000884710 uncertain significance not provided 2018-01-12 criteria provided, single submitter clinical testing The TNFRSF1A c.269C>T; p.Thr90Ile variant, also known as Thr61Ile, is published in the medical literature in several individuals with suspected TRAPS (Ida 2004, Ohmori 2014, Ueda 2016), but has also been published at a similar frequency in control individuals from the same ethnic group (Ida 2004, Ueda 2016). The variant is not listed in the ClinVar database, but is listed in the dbSNP variant database (rs34751757). The variant is described in the Genome Aggregation Database in 0.1 percent (20/13848 alleles) of the East Asian population. The threonine at this position is conserved across species and computational algorithms (PolyPhen2, SIFT) predict this variant is deleterious. Additionally, another variant in the same amino acid, p.Thr90Pro, is published in an individual with suspected TRAPS and the variant appeared to segregate with disease. However, due to conflicting information, this variant cannot be classified with certainty. Pathogenic TNFRSF1A variants are associated with autosomal dominant periodic fever (MIM#142680). References: Ida H et al. A novel mutation (T61I) in the gene encoding tumour necrosis factor receptor superfamily 1A (TNFRSF1A) in a Japanese patient with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) associated with systemic lupus erythematosus. Rheumatology (Oxford). 2004 Oct;43(10):1292-9. Ohmori S et al. Inflammatory response to heparinoid and heparin in a patient with tumor necrosis factor receptor-associated periodic syndrome: the second case with a T61I mutation in the TNFRSF1A gene. J Dermatol. 2014 Dec;41(12):1112-3. Ueda N et al. Clinical and Genetic Features of Patients With TNFRSF1A Variants in Japan: Findings of a Nationwide Survey. Arthritis Rheumatol. 2016 Nov;68(11):2760-2771. Radhakrishna SM et al. Novel mutation identified in severe early-onset tumor necrosis factor receptor-associated periodic syndrome: a case report. BMC Pediatr. 2017 Apr 20;17(1):108.
Illumina Laboratory Services, Illumina RCV001078480 SCV001268766 uncertain significance TNF receptor-associated periodic fever syndrome (TRAPS) 2017-04-27 criteria provided, single submitter clinical testing This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.